VC: Gemin X leads with $65M second round



Gemin X leads with $65M second round.

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Gemin X
Montreal

$65.2M
second round

H.I.G., Sanderling

Funding will support Gemin X's continued clinical development of lead product candidate GX15-070, including an ongoing Phase I/II trial in patients with chronic lymphocytic leukemia and a Phase I trial in patients with solid tumors.

Oxagen
Abingdon, UK

$59.8M
second round

MPM Capital

The funds will advance Oxagen's small molecule anti-inflammatory for asthma to the clinic and expand the company's clinical and pre-clinical stage portfolio.

Phenomix
San Diego

$40M
second round

JPMorgan Partners, Delphi Ventures

The money will allow Phenomix to steer its lead drug into human trials.

Cylene Pharmaceuticals
San Diego

$26.3M
second round

Coastview Capital

The funding will allow Cylene to advance CX-3543, its lead product for the treatment of multiple cancers, into clinical development.

Aperon Biosystems
Palo Alto, CA

$15.3M
second round

Canaan Partners

Aperon is developing an in-home monitor for daily measurement of exhaled nitric oxide for the management of asthma.

Innovative Biosensors
College Park, MD

$3.5M
first round

Harbert Venture Partners

Innovative Biosensors is developing technologies for the rapid detection of pathogens.

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.